Clinical Trials
7
Active:0
Completed:1
Trial Phases
3 Phases
Phase 1:1
Phase 3:3
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 3
3 (60.0%)Not Applicable
1 (20.0%)Phase 1
1 (20.0%)A Multicentre Study to Explore the Efficacy and Safety of Mucopolysaccharide Polysulfate Cream in Patients With Eczema
- Conditions
- Eczema
- Interventions
- Drug: Mucopolysaccharide Polysulfate CreamDrug: Mucopolysaccharide Polysulfate Cream and glucocorticoids
- First Posted Date
- 2022-06-30
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- Shenzhen Kangzhe Pharmaceutical Co., Ltd.
- Target Recruit Count
- 1800
- Registration Number
- NCT05439577
- Locations
- 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection (Lipodox®) in Chinese Patients
Phase 1
- Conditions
- Ovarian CancerBreast Cancer
- Interventions
- First Posted Date
- 2022-03-10
- Last Posted Date
- 2022-03-10
- Lead Sponsor
- Shenzhen Kangzhe Pharmaceutical Co., Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT05273944
- Locations
- 🇨🇳
Sun Yat-Sun Memorial Hospital, Sun Yat-Sun University, Guangzhou, Guangdong, China
A Phase Ⅲ Study to Evaluate Tildrakizumab in the Treatment of Chinese Subjects With Moderate to Severe Plaquetype Psoriasis
- First Posted Date
- 2021-11-05
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- Shenzhen Kangzhe Pharmaceutical Co., Ltd.
- Target Recruit Count
- 220
- Registration Number
- NCT05108766
- Locations
- 🇨🇳
The First Affiliated Hospital of Air Force Medical University of PLA, Xi'an, China
A Study of Oryz-Aspergillus Enzyme and Pancreatin Tablet in Patients With Cirrhosis and Malnutrition
Not Applicable
- Conditions
- Cirrhosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-08-15
- Last Posted Date
- 2019-08-15
- Lead Sponsor
- Shenzhen Kangzhe Pharmaceutical Co., Ltd.
- Target Recruit Count
- 132
- Registration Number
- NCT04057326
Expanding Phase III Study of Tyroserleutide for Injection
Phase 3
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2018-05-04
- Last Posted Date
- 2018-05-04
- Lead Sponsor
- Shenzhen Kangzhe Pharmaceutical Co., Ltd.
- Target Recruit Count
- 352
- Registration Number
- NCT03516448
- Prev
- 1
- 2
- Next
News
No news found